Skip to content
ARVO 2024 presentation: Synthetic Peptide Hydrogel-Based Human In Vitro Corneal Model​

ARVO 2024 presentation: Synthetic Peptide Hydrogel-Based Human In Vitro Corneal Model​

Synthetic peptide hydrogels are promising scaffolds where cornea epithelium and other cell types can be grown into in vitro cultures. The aim of this study was to develop a corneal model employing a peptide hydrogel layer as a mimetic of corneal stroma. The model was used in the assessment of corneal cytotoxicity and penetration properties of prostaglandin analogs that are considered as first-line treatment for glaucoma.

Learn more Arrow right
ARVO 2024 presentation: Neural Network-Based Isolectin B4 Flat-Mount Analysis in a Novel AAV-hVEGF-Induced Diabetic Retinopathy Animal Model​​

ARVO 2024 presentation: Neural Network-Based Isolectin B4 Flat-Mount Analysis in a Novel AAV-hVEGF-Induced Diabetic Retinopathy Animal Model​​

Diabetic retinopathy (DR) is a complex disease displaying diverse vascular-associated complications, including upregulation of vascular endothelial growth factor (VEGF)-A165, enhanced vascular permeability, and retinal angiogenesis. Current animal models do not fully replicate the spectrum of DR pathologies. In this study, we aim to evaluate the efficacy of adeno-associated virus (AAV)-mediated long-term expression of human VEGF to establish angiogenic DR-related phenotypes in Brown Norway rats, as well as validate a novel artificial intelligence (AI) framework for autonomous quantification of retinal angiogenesis in a newly established DR model.​

Learn more Arrow right
AAALAC accredited company

All our facilities are AAALAC accredited, reflecting our commitment to the highest standards of animal care in research.